News & Events

Combo Exhibits Activity in KRAS-Mutant, Advanced NSCLC

Combo Exhibits Activity in KRAS-Mutant, Advanced NSCLC

KRAS G12C in Advanced NSCLC: Prevalence, Co-Mutations, and Testing

KRAS G12C in Advanced NSCLC: Prevalence, Co-Mutations, and Testing

What Makes Olomorasib a Promising Option for KRAS G12C-Mutant NSCLC Patients?

What Makes Olomorasib a Promising Option for KRAS G12C-Mutant NSCLC Patients?

KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC

KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC

FDA Grants Breakthrough Therapy Designation to Olomorasib is KRAS G12C NSCLC

FDA Grants Breakthrough Therapy Designation to Olomorasib is KRAS G12C NSCLC

Therapy for KRAS G12C-Mutated Cancers Gets Breakthrough, Orphan Designations

Therapy for KRAS G12C-Mutated Cancers Gets Breakthrough, Orphan Designations

Adagrasib Shows Improved Progression-Free Survival Over Docetaxel in KRAS G12C-Mutated NSCLC Study

Adagrasib Shows Improved Progression-Free Survival Over Docetaxel in KRAS G12C-Mutated NSCLC Study

Adagrasib Shows Improved Progression-Free Survival Over Docetaxel in KRAS G12C-Mutated NSCLC Study

Adagrasib Shows Improved Progression-Free Survival Over Docetaxel in KRAS G12C-Mutated NSCLC Study

Promising Trial Data Leads to Breakthrough Designation for Eli Lilly’s Investigational KRAS G12C Inhibitor in Advanced, Metastatic Non-Small Cell Lung Cancer

Promising Trial Data Leads to Breakthrough Designation for Eli Lilly’s Investigational KRAS G12C Inhibitor in Advanced, Metastatic Non-Small Cell Lung Cancer

Novel Therapy for KRAS G12C-Mutated Cancers Gets Breakthrough Tx, Orphan Drug Designations

Novel Therapy for KRAS G12C-Mutated Cancers Gets Breakthrough Tx, Orphan Drug Designations